Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Background: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a com...

Full description

Bibliographic Details
Main Authors: T. Hedley Carr, Carrie Adelman, Alan Barnicle, Iwanka Kozarewa, Sally Luke, Zhongwu Lai, Sally Hollis, Brian Dougherty, Elizabeth A. Harrington, Jinyu Kang, Fred Saad, Nuria Sala, Antoine Thiery-Vuillemin, Noel W. Clarke, Darren Hodgson, J. Carl Barrett
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
circulating tumour DNA (ctDNA)
homologous recombination repair (HRR)
prostate cancer
next-generation sequencing (NGS)
PARP inhibition
metastasis
Online Access:https://www.mdpi.com/2072-6694/13/22/5830

Internet

https://www.mdpi.com/2072-6694/13/22/5830

Similar Items